01444nas a2200277 4500000000100000008004100001260001700042653001800059653002600077653001600103653001100119653001200130653001200142653002500154653003000179653002000209653002100229653001400250100001700264245008800281856005400369300000900423490000700432520071300439022001401152 2008 d c2008 Jan-Feb 10 aBinding Sites 10 aComputational Biology 10 aDrug Design 10 aHumans 10 aleprosy 10 aLigands 10 aMycobacterium leprae 10 aPredictive Value of Tests 10 aProtein Binding 10 aReceptor, erbB-2 10 aVirulence 1 aWiwanitkit V 00 aLigand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy. uhttp://www.ijdvl.com/text.asp?2008/74/1/32/38404 a32-4 0 v74 3 aBACKGROUND AND AIMS: Mycobacterium leprae is an obligate intracellular pathogen. Ligand-binding is an important factor in the success of chemoprevention and chemotherapy. A new drug that can inhibit M. leprae binding to and activation of, ErbB2 and Erk1/2 in primary Schwann cells is the new therapeutic option. However, the ligand-binding pattern of ErbB2 has never been clarified.
METHODS: In this work, the author performed a ligand-binding prediction for ErbB2 using a new bioinformatics tool.
RESULTS: According to this study, nine strong possible ligands can be identified.
CONCLUSION: These sites can be useful for further drug-development studies.
a0973-3922